{"analyses":[{"ciLowerLimit":"1.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.13","estimateComment":"Hazard ratio is for Rituximab Retreatment Arm/Rituximab Scheduled Arm in follicular patients.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.002","paramType":"Hazard Ratio (HR)","paramValue":"3.21","statisticalMethod":"Log Rank"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0002","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.78","upperLimit":"0.90","value":"0.84"},{"groupId":"OG001","lowerLimit":"0.91","upperLimit":"0.99","value":"0.95"},{"groupId":"OG002","lowerLimit":"0.55","upperLimit":"0.94","value":"0.72"},{"groupId":"OG003","lowerLimit":"1","upperLimit":"1","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"TTFC is defined as the time from randomization to the time of first cytotoxic therapy (chemo and radio therapy), and censored as last follow-up time if no cytotoxic therapy has been used. Since median TTFC was not reached in 3 out of the 4 groups, 3-year TTFC was reported which was defined as the probability of not starting first cytotoxic therapy at 3 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG000","title":"Rituximab Retreatment: Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG001","title":"Rituximab Scheduled: Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG002","title":"Rituximab Retreatment: Non-Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG003","title":"Rituximab Scheduled: Non-Follicular Patients"}],"paramType":"NUMBER","populationDescription":"Patients who were correctly randomized to one of the two maintenance arms.","reportingStatus":"POSTED","timeFrame":"Assessed every 13 weeks until rituximab failure observed or August 2013, whichever occurred first.","title":"Time to First Cytotoxic Therapy (TTFC)","type":"SECONDARY","unitOfMeasure":"probability"}